Status:
UNKNOWN
Infantile NO Replenishment as a New Therapeutic Possibility
Lead Sponsor:
National and Kapodistrian University of Athens
Collaborating Sponsors:
URI-NKUA
University Hospital, Lille
Conditions:
Prematurity
Respiratory Distress Syndrome, Newborn
Eligibility:
All Genders
1-3 years
Brief Summary
Case-control study of inhaled Nitric Oxide (iNO) treatment of full-term and preterm infants. The main objective of this study is to investigate the association between premature birth and its later co...
Detailed Description
In preterm infants, inhaled NO (iNO) is routinely used to treat respiratory failure and pulmonary hypertension, while preclinical studies have shown that it markedly increases NO concentrations in the...
Eligibility Criteria
Inclusion
- Preterm (GA\<37 weeks) or full-term (≥37 weeks of gestation) infants
- Requiring respiratory support
- Admitted to Neonatal Care Unit
Exclusion
- Severe congenital anomalies
- Suspected major chromosomal anomalies
- Infants judged by the physician as nonviable
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT04914806
Start Date
June 1 2021
End Date
December 31 2025
Last Update
December 21 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Regional Et Universitaire de Lille
Lille, France, 59037
2
URI-NKUA
Athens, Greece, 11527
3
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, 1005